TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yuan, Xianglin ^a   Wei, Qingyi ^b   Komaki, Ritsuko ^b   Liu, Zhensheng ^b   Yang, Ju ^a   Tucker, Susan L ^b   Xu, Ting ^b   Heymach, John V ^b   Lu, Charles ^b   Cox, James D ^b   Liao, Zhongxing ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUMOR INVASION; TUMOR VOLUME; A-549 CELL LINE; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DISEASE FREE SURVIVAL; GENETICS; LUNG TUMOR; METASTASIS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

A549 CELLS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84879247016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065659     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA: Cancer J Clin 62: 10-29.
2. Massague J, (1998) TGF-beta signal transduction. Annual Review of Biochemistry 67: 753-791.
3. Massague J, Gomis RR, (2006) The logic of TGFbeta signaling. FEBS Letters 580: 2811-2820.
4. Roberts AB, (1999) TGF-beta signaling from receptors to the nucleus. Microbes Infect 1: 1265-1273.
5. Finger EC, Turley RS, Dong M, How T, Fields TA, et al. (2008) TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29: 528-535.
6. Kang Y, Prentice MA, Mariano JM, Davarya S, Linnoila RI, et al. (2000) Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis. Exp Lung Res 26: 685-707.
7. Kato Y, Habas R, Katsuyama Y, Naar AM, He X, (2002) A component of the ARC/Mediator complex required for TGF beta/Nodal signalling. Nature 418: 641-646.
8. Jeon HS, Dracheva T, Yang SH, Meerzaman D, Fukuoka J, et al. (2008) SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 68: 9686-9692.
9. Jakowlew SB, (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457.
10. Tsuchida K, Sunada Y, Noji S, Murakami T, Uezumi A, et al. (2006) Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev Med Chem 6: 1255-1261.
11. Saunier EF, Akhurst RJ, (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6: 565-578.
12. Derynck R, Akhurst RJ, Balmain A, (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
13. Wakefield LM, Roberts AB, (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002 12: 22-29.
14. Fong YC, Hsu SF, Wu CL, Li TM, Kao ST, et al. (2009) Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer 64: 13-21.
15. Vicent S, Luis-Ravelo D, Anton I, Garcia-Tunon I, Borras-Cuesta F, et al. (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 68: 2275-2285.
16. Tiwari N, Gheldof A, Tatari M, Christofori G, (2012) EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207.
17. Chorna I, Fedorenko O, Datsyuk L, Stoika R, (2005) Expression of mRNA coding for TGF-beta and its receptors in irradiated human breast carcinoma MCF-7 cells differing in their sensitivity to doxorubicin. Exp Oncol 27: 156-158.
18. Saji H, Nakamura H, Awut I, Kawasaki N, Hagiwara M, et al. (2003) Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg 9: 295-300.
19. Suardet L, Li C, Little JB, (1996) Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. Int J Cancer 68: 126-131.
20. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ, (2004) Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71: 183-189.
21. Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, et al. (2008) The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59: 232-239.
22. Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, et al. (2005) TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 75: 18-21.
23. De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, et al. (2006) TGF[beta]1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 65: 1240-1248.
24. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, et al. (2009) Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 27: 3370-3378.
25. Shu XO, Gao YT, Cai Q, Pierce L, Cai H, et al. (2004) Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 64: 836-839.
26. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J, (2004) A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 13: 759-764.
27. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, et al. (2003) A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63: 2610-2615.
28. Slattery ML, Herrick JS, Lundgreen A, Wolff RK, (2011) Genetic variation in the TGF-beta signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 20: 57-69.
29. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59: 1874-1881.
30. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, et al. (1998) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42: 469-478.
31. Andre F, Grunenwald D, Pujol JL, Girard P, Dujon A, et al. (2001) Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer 91: 2394-2400.
32. Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA, (2007) Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 109: 1668-1675.
33. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37: 745-751.
34. Penel N, Brichet A, Prevost B, Duhamel A, Assaker R, et al. (2001) Pronostic factors of synchronous brain metastases from lung cancer. Lung Cancer 33: 143-154.
35. Ampil F, Caldito G, Milligan S, Mills G, Nanda A, (2007) The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? Lung Cancer 57: 60-65.
36. Nguyen TD, DeAngelis LM (2007) Brain metastases. Neurol Clin 25: 1173-1192, x-xi.
37. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, et al. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363: 1665-1672.
38. Pottgen C, Eberhardt W, Grannass A, Korfee S, Stuben G, et al. (2007) Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 25: 4987-4992.
39. Yavuz AA, Topkan E, Onal C, Yavuz MN, (2008) Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients. J Exp Clin Cancer Res 27: 80.
40. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, et al. (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29: 272-278.
41. Hu Z, Huo X, Lu D, Qian J, Zhou J, et al. (2005) Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 11: 5433-5439.
42. Fang SM, Jin X, Li Y, Wang R, Guo W, et al. (2005) [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer]. Ai Zheng 24: 305-310.
43. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, et al. (2005) The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 63: 885-891.
44. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, et al. (2001) Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964-971.
45. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS, (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86: 1712-1719.
46. Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R, (2006) Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp (Warsz) 54: 143-147.
47. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, et al. (1998) Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014-1020.
48. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, et al. (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8: 93-97.
49. Mu L, Katsaros D, Lu L, Preti M, Durando A, et al. (2008) TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer 99: 1357-1363.